Comorbid psoriasis-bipolar disorder successfully treated with apremilast: much more than a mere coincidence?

• Main Authors: Muhammed Razmi T, N A Uvais, S V Rakhesh, T P Afra, N A Bishurul Hafi
• Format: Article
• Language: English
• Published: BMJ Publishing Group 2020-06-01
• Series: General Psychiatry
• Online Access: https://gpsych.bmj.com/content/33/3/e100181.full

Psoriasis is a chronic, immune mediated, systemic inflammatory skin disease with a reported prevalence of 0.6%–4.8% in the general population. Bipolar disorder (BP) is a severe episodic psychiatric disorder that ranks as the fourth leading cause of disability. Recent evidence suggests that genetic and immunological factors play a significant role in the development of both disorders. Studies have also shown a higher association of psychiatric disorders among patients with psoriasis. Moreover, several autoimmune comorbidities have been reported in association with BP. Here, we describe a young woman with BP who developed psoriasis after 1 year of developing BP and showed exacerbations in psoriasis lesions with each manic episode. We also highlight the safe and efficacious use of apremilast for psoriatic lesions in the woman.